HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 4, Pages 638
Publisher
MDPI AG
Online
2021-02-08
DOI
10.3390/cancers13040638
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial
- (2020) John A Bridgewater et al. LANCET ONCOLOGY
- HER4 promotes the progression of colorectal cancer by promoting epithelial‑mesenchymal transition
- (2020) Xiaojing Jia et al. Molecular Medicine Reports
- A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
- (2020) Salvatore Siena et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
- (2019) Said Abdullah Khelwatty et al. Oncotarget
- Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer
- (2019) G. Wang et al. Clinical & Translational Oncology
- Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?
- (2018) M. Baretti et al. CANCER BIOLOGY & THERAPY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
- (2018) Luca Falzone et al. Frontiers in Pharmacology
- Necitumumab: First Global Approval
- (2016) Karly P. Garnock-Jones DRUGS
- Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers
- (2016) Sofie Ellebaek et al. INTERNATIONAL JOURNAL OF CANCER
- A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
- (2016) James M. Cleary et al. INVESTIGATIONAL NEW DRUGS
- ExtendedRASGene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
- (2016) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
- (2016) Said Khelwatty et al. Oncotarget
- Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
- (2015) Said A Khelwatty et al. BRITISH JOURNAL OF CANCER
- RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp).
- (2015) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer
- (2015) Hanna Styczen et al. Oncotarget
- Expression of HER-2 in Rectal Cancers Treated With Preoperative Radiotherapy
- (2014) Yun-Feng Yao et al. DISEASES OF THE COLON & RECTUM
- Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer
- (2014) YUKI SEO et al. ONCOLOGY REPORTS
- Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival
- (2014) Said Abdullah Khelwatty et al. PLoS One
- Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers
- (2013) Monica Dandona Desai et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Prognostic significance and targeting of HER family in colorectal cancer
- (2013) Helmout Modjtahedi Frontiers in Bioscience-Landmark
- Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer
- (2013) John Marshall et al. Future Oncology
- Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients WithKRASWild-Type Unresectable Colorectal Liver-Limited Metastases
- (2013) Le-Chi Ye et al. JOURNAL OF CLINICAL ONCOLOGY
- Food and Drug Administration Approval of Cetuximab and a New KRAS Genetic Test for Metastatic Colorectal Cancer
- (2012) Ronald Lieberman AMERICAN JOURNAL OF THERAPEUTICS
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
- (2012) S. Stintzing et al. ANNALS OF ONCOLOGY
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
- (2012) Douglas G. Altman et al. PLOS MEDICINE
- HER2 Signaling and Resistance to the Anti-EGFR Monoclonal Antibody Cetuximab: A Further Step toward Personalized Medicine for Patients with Colorectal Cancer
- (2011) F. Ciardiello et al. Cancer Discovery
- Targeted treatments in colorectal cancer: state of the art and future perspectives
- (2010) D. Arnold et al. GUT
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
- (2009) Helmout Modjtahedi et al. ANTI-CANCER DRUGS
- ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery
- (2009) Glauco Baiocchi et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking
- (2009) I. H. Madshus et al. JOURNAL OF CELL SCIENCE
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panitumumab: Human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer
- (2008) Mei Wu et al. CLINICAL THERAPEUTICS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Endocytosis and intracellular trafficking of ErbBs
- (2008) Alexander Sorkin et al. EXPERIMENTAL CELL RESEARCH
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started